Allurion Technologies (ALUR) Cash from Financing Activities (2022 - 2026)
Allurion Technologies (ALUR) posted Cash from Financing Activities of $2.9 million for Q1 2026, down 37.65% on a QoQ basis from $4.6 million in Q4 2025, and down 80.23% year-over-year from $14.5 million in Q1 2025.
Allurion Technologies (ALUR) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Allurion Technologies' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 80.23% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 78.62% YoY) and the FY2025 annual result came in at $19.0 million, down 6.13% from the prior year.
- Cash from Financing Activities was $2.9 million for Q1 2026 at Allurion Technologies, down from $4.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $98.9 million in Q3 2023 and bottomed at -$20.4 million in Q4 2023.
- A 5-year average of $10.8 million and a median of $4.6 million in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 239.4% — and 2025, when it surged 8773.58%.
- Allurion Technologies' Cash from Financing Activities stood at $14.6 million in 2022, then slumped by 239.4% to -$20.4 million in 2023, then soared by 99.74% to -$53000.0 in 2024, then jumped by 8773.58% to $4.6 million in 2025, then plunged by 37.65% to $2.9 million in 2026.
- Business Quant data shows ALUR's Cash from Financing Activities at $2.9 million in Q1 2026, $4.6 million in Q4 2025, and -$55000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Allurion Technologies | 74.67 Mn | 69.62 Mn | 1.23 Mn | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | -55,000.00 |
| Sep 30, 2025 | -55,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | 14.50 Mn |
| Mar 31, 2025 | 14.50 Mn |
| Dec 31, 2024 | -53,000.00 |
| Dec 31, 2024 | -53,000.00 |
| Sep 30, 2024 | 20.93 Mn |
| Sep 30, 2024 | 20.93 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Mar 31, 2024 | 387,000.00 |
| Mar 31, 2024 | 387,000.00 |
| Dec 31, 2023 | -20.41 Mn |
| Dec 31, 2023 | -20.41 Mn |